The US Congress signs legislation aimed at reducing prescription drug prices by supporting generic and biosimilar alternatives to branded drugs

On April 23, 2021, President Biden signed into law two bipartisan bills aimed at reducing prescription drug prices by supporting generic and biosimilar alternatives to branded drugs. The Ensuring Innovation Act supports generic drugs by clarifying the technical qualifications for earning exclusivity as a "new chemical entity." The Advancing Education on Biosimilars Act provides for increased federal efforts to educate patients, doctors and caregivers about biosimilar drugs. These changes come as proposals for more comprehensive legislation on drug pricing, such as allowing Medicare to negotiate prices directly with manufacturers, have thus far been excluded from the Biden Administration’s major spending initiatives. Below is a short summary of each new bill. The Ensuring

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteurs

  • White & Case (New York)
  • White & Case (New York)

Citation

Michael Gallagher, Kevin Adam, The US Congress signs legislation aimed at reducing prescription drug prices by supporting generic and biosimilar alternatives to branded drugs, 23 avril 2021, e-Competitions April 2021, Art. N° 100819

Visites 170

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues